Omni C&S, a Korean digital healthcare company, said Tuesday that it has received marketing authorization from the Thailand Food and Drug Administration for its electroencephalogram (EEG) and photoplethysmography (PPG) measurement device, Omnifit Mindcare.

Omnifit Mindcare measures EEG and PPG to provide personalized solutions by analyzing stress levels, brain health, and autonomic nerve health.

With this approval, Omni C&S plans to start marketing Omnifit Mindcare in Thailand after discussions with local distributors and partners.

Omnifit Mindcare is equipped with Neuronicle FX2, a device that measures the signal of EEG and PPG, transmitting measured data through Bluetooth communication.

According to Omni C&S, Thailand's medical device market continues to grow, driven by an aging population, increased medical tourism, the Thai government's efforts to promote the healthcare industry, and the expansion of new private hospitals.

In particular, psychological and mental care, such as rehabilitation treatment for drug addicts and an increase in the number of workers suffering from burnout after Covid-19, are gaining attention as social concerns in Thailand.

Omni C&S expects its overseas performance to become visible as Thailand opens up for sales after the U.S., Singapore, and Middle East countries.

"As the Thailand FDA approval is smoothly finalized, we plan to speed up our efforts to penetrate the Thai market," an Omni C&S official said. "We are also expecting the U.S. and European approvals, looking forward to significant international growth."